头颈部癌症的遗传特征及其治疗意义
Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
机构信息
Wake Forest School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC.
Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA.
出版信息
Semin Radiat Oncol. 2018 Jan;28(1):2-11. doi: 10.1016/j.semradonc.2017.08.005.
Abstract
Large-scale sequencing studies of head and neck squamous cell carcinoma (HNSCC) have elucidated the genetic changes that characterize HNSCC. These findings have supported the development of therapeutic strategies that target key components of aberrant signaling pathways and immune dysregulation. Cumulative evidence suggests that these agents in combination with radiotherapy may have synergistic effects. This review highlights the predictive biomarkers that have been identified from HNSCC genomic studies and implications on the development of molecular-targeting agents that may effectively treat patients with HNSCC, especially when used in combination with radiation.
摘要
大规模的头颈部鳞状细胞癌（HNSCC）测序研究阐明了HNSCC 的遗传变化。这些发现支持了开发治疗策略的发展，这些策略针对异常信号通路和免疫失调的关键成分。累积的证据表明，这些药物与放疗联合使用可能具有协同作用。本综述强调了从 HNSCC 基因组研究中确定的预测生物标志物及其对分子靶向药物开发的影响，这些药物可能对头颈部鳞状细胞癌患者有效治疗，尤其是与放疗联合使用时。
相似文献
1
Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.头颈部癌症的遗传特征及其治疗意义
Semin Radiat Oncol. 2018 Jan;28(1):2-11. doi: 10.1016/j.semradonc.2017.08.005.
2
mTOR co-targeting strategies for head and neck cancer therapy.用于头颈癌治疗的mTOR共靶向策略。
Cancer Metastasis Rev. 2017 Sep;36(3):491-502. doi: 10.1007/s10555-017-9688-7.
3
Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.头颈部鳞状细胞癌的新型治疗方法：临床前鉴定与临床研究。
Future Oncol. 2014 May;10(6):1065-80. doi: 10.2217/fon.14.18.
4
Insights into metastatic roadmap of head and neck cancer squamous cell carcinoma based on clinical, histopathological and molecular profiles.基于临床、组织病理学和分子特征对头颈部鳞状细胞癌转移途径的深入了解。
Mol Biol Rep. 2024 Apr 29;51(1):597. doi: 10.1007/s11033-024-09476-8.
5
Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.头颈部鳞状细胞癌基因组研究的治疗见解
Cancer Discov. 2015 Mar;5(3):239-44. doi: 10.1158/2159-8290.CD-14-1205. Epub 2015 Feb 2.
6
Leveraging Genomics for Head and Neck Cancer Treatment.利用基因组学进行头颈部癌症治疗。
J Dent Res. 2018 Jun;97(6):603-613. doi: 10.1177/0022034518756352. Epub 2018 Feb 8.
7
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.靶向表皮生长因子受体-磷脂酰肌醇-3-激酶-蛋白激酶B-哺乳动物雷帕霉素靶蛋白信号通路可增强头颈部鳞状细胞癌的放射敏感性。
Expert Opin Ther Targets. 2015 Jun;19(6):795-805. doi: 10.1517/14728222.2015.1012157. Epub 2015 Feb 5.
8
Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.头颈部鳞状细胞癌的免疫疗法：当前及新兴治疗选择综述
Oncologist. 2017 Jun;22(6):680-693. doi: 10.1634/theoncologist.2016-0318. Epub 2017 May 15.
9
Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.原发性头颈部鳞状细胞癌细胞中微小RNA-信使核糖核酸对放化疗反应的综合分析
BMC Genomics. 2015 Sep 2;16(1):654. doi: 10.1186/s12864-015-1865-x.
10
MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.MiR-21作为接受器官保留方案的头颈部鳞状细胞癌患者的预后生物标志物。
Oncotarget. 2017 Feb 7;8(6):9911-9921. doi: 10.18632/oncotarget.14253.
引用本文的文献
1
In Silico Discovery of a Novel Potential Allosteric PI3Kα Inhibitor Incorporating 3-(2-Chloro-5-fluorophenyl)isoindolin-1-one to Target Head and Neck Squamous Cell Carcinoma.基于计算机模拟发现一种新型潜在变构PI3Kα抑制剂，其包含3-(2-氯-5-氟苯基)异吲哚啉-1-酮，用于靶向头颈部鳞状细胞癌。
Biology (Basel). 2025 Jul 21;14(7):896. doi: 10.3390/biology14070896.
2
Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy-a review.网络药理学：口腔、头颈癌治疗中一种高效但未充分利用的方法——综述
Front Pharmacol. 2024 Jul 5;15:1410942. doi: 10.3389/fphar.2024.1410942. eCollection 2024.
3
VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating mRNA and m6A levels.VIRMA 通过调节 mRNA 和 m6A 水平促进头颈部鳞状细胞癌的进展。
Biomol Biomed. 2024 Sep 6;24(5):1244-1257. doi: 10.17305/bb.2024.10358.
4
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer.无瘤切除边缘的联合TP53状态与循环微RNA谱分析可预测头颈癌局部区域复发风险。
Biomark Res. 2024 Mar 5;12(1):32. doi: 10.1186/s40364-024-00576-y.
5
Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.表皮生长因子受体抑制剂对 PI3K/Akt/mTOR 活性的差异调节：顺铂耐药头颈部鳞状细胞癌中共同靶向 EGFR 和 PI3K 的原理。
Head Neck. 2024 May;46(5):1126-1135. doi: 10.1002/hed.27718. Epub 2024 Mar 1.
6
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma.与口咽鳞状细胞癌中HPV整合引起的炎症反应相关的基因突变
Biomedicines. 2023 Dec 21;12(1):24. doi: 10.3390/biomedicines12010024.
7
Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy.口腔微生物群失调和人乳头瘤病毒感染在头颈癌中的影响：从分子和细胞机制到早期诊断与治疗
Front Oncol. 2023 Dec 18;13:1273516. doi: 10.3389/fonc.2023.1273516. eCollection 2023.
8
Angiopoietin-like 4 induces head and neck squamous cell carcinoma cell migration through the NRP1/ABL1/PXN pathway.血管生成素样蛋白 4 通过 NRP1/ABL1/PXN 通路诱导头颈部鳞状细胞癌细胞迁移。
Cell Signal. 2023 Aug;108:110697. doi: 10.1016/j.cellsig.2023.110697. Epub 2023 May 9.
9
Targeted therapy for head and neck cancer: signaling pathways and clinical studies.头颈部癌症的靶向治疗：信号通路与临床研究。
Signal Transduct Target Ther. 2023 Jan 16;8(1):31. doi: 10.1038/s41392-022-01297-0.
10
Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions.口腔癌前病变中 EGFR、CDKN2A 和 CCND1 的反复拷贝数改变。
J Oral Pathol Med. 2022 Jul;51(6):546-552. doi: 10.1111/jop.13303. Epub 2022 May 20.
本文引用的文献
1
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.基底亚型可预测头颈部鳞状细胞癌患者来源异种移植模型对西妥昔单抗治疗的反应。
Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21.
2
Advances in Radiation Oncology: What to Consider.放射肿瘤学进展：需考虑的因素
Otolaryngol Clin North Am. 2017 Aug;50(4):755-764. doi: 10.1016/j.otc.2017.03.011. Epub 2017 May 17.
3
Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.头颈部鳞状细胞癌放射敏感性的生物学预测因子。
Clin Oral Investig. 2018 Jan;22(1):189-200. doi: 10.1007/s00784-017-2099-x. Epub 2017 Mar 18.
4
Inhibitors of cyclin-dependent kinases as cancer therapeutics.细胞周期蛋白依赖性激酶抑制剂作为癌症治疗药物
Pharmacol Ther. 2017 May;173:83-105. doi: 10.1016/j.pharmthera.2017.02.008. Epub 2017 Feb 5.
5
Integrated genomic and molecular characterization of cervical cancer.宫颈癌的综合基因组和分子特征分析
Nature. 2017 Mar 16;543(7645):378-384. doi: 10.1038/nature21386. Epub 2017 Jan 23.
6
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.PI3K通路失调与头颈部鳞状细胞癌的靶向治疗
Oncotarget. 2017 Mar 28;8(13):22203-22217. doi: 10.18632/oncotarget.14729.
7
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.H3K36甲基化受损定义了头颈部鳞状细胞癌的一个子集。
Nat Genet. 2017 Feb;49(2):180-185. doi: 10.1038/ng.3757. Epub 2017 Jan 9.
8
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.E1308：诱导化疗后降低剂量放疗联合西妥昔单抗每周治疗人乳头瘤病毒相关可切除口咽鳞状细胞癌患者的II期试验 - ECOG-ACRIN癌症研究组
J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.
9
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.一种基于基因组的放疗剂量调整模型（GARD）：一项基于队列的回顾性研究。
Lancet Oncol. 2017 Feb;18(2):202-211. doi: 10.1016/S1470-2045(16)30648-9. Epub 2016 Dec 18.
10
Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.全基因组关联分析确定口腔和咽癌的新易感基因座。
Nat Genet. 2016 Dec;48(12):1544-1550. doi: 10.1038/ng.3685. Epub 2016 Oct 17.
Zotero 插件